RoslinCT has been awarded an R&D grant of up to £7.25 million from Scottish Enterprise to accelerate the digital transformation of its cell therapy manufacturing operations in Scotland.
The grant supports a multi-year digital expansion initiative intended to strengthen RoslinCT’s integrated digital and artificial intelligence capabilities.
RoslinCT is a cell therapy contract development and manufacturing organization supporting developers across process development, analytical development, GMP manufacturing and preparation for commercial production.
The new program will focus on developing a more digitally integrated manufacturing environment across the company’s Scottish operations.
RoslinCT expects the initiative to improve operational efficiency, data connectivity and manufacturing performance.
The company sees digital infrastructure as increasingly important as advanced cell therapies move from clinical development toward larger-scale commercial manufacturing.
More connected manufacturing data can potentially help identify process issues earlier, improve consistency and allow customers to progress therapies through development more efficiently.
RoslinCT said the project will support both clinical and commercial cell therapy production while contributing to employment and economic growth in Scotland’s life sciences industry.
The company has operated in Scotland for approximately two decades and has participated in the development and manufacturing of therapies targeting cancer, genetic disorders and other complex diseases.
The Scottish Enterprise support is intended to help RoslinCT continue investing in advanced manufacturing infrastructure as international competition in cell and gene therapy production increases.
KEY QUOTES:
“This support from Scottish Enterprise represents an important investment in the future of advanced therapy manufacturing in Scotland. Digital technologies are transforming how cell therapies are developed and manufactured, enabling greater efficiency, consistency and scalability while maintaining the highest quality standards.
At RoslinCT, we are committed to building world-class manufacturing capabilities that help our clients bring innovative therapies to patients faster. This programme will strengthen our digital infrastructure, support continued innovation and reinforce Scotland’s position as a leading destination for cell and gene therapy manufacturing.”
Peter Coleman, Chief Executive Officer of RoslinCT
“Scotland’s life sciences sector has built a strong international reputation for innovation and expertise, and RoslinCT’s ambitious digital programme demonstrates their continued leadership in this field.
This R&D project is a prime example of how Scottish Enterprise support can enable innovation at scale and strengthen competitiveness in global markets.”
Adrian Gillespie, Chief Executive of Scottish Enterprise
“This Scottish Enterprise grant is good news for Edinburgh, good news for Scotland’s life sciences sector and good news for the advancement of vitally important work that is improving and saving lives across the world.
Over the last twenty years, RoslinCT has established itself as a Scottish success story, delivering and manufacturing life-changing therapies for cancer, genetic disorders and other complex medical conditions.
The Scottish Government and our enterprise agencies recognise the importance of helping our life sciences sector remain internationally competitive and will continue supporting and investing in our fantastic, world-renowned innovation.”
Tom Arthur, Minister for Business & Fair Work
